Daily Briefing · Issue №010 · 2026-05-24

Pharmacy

Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust los

• Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with reports of three positive phase 3 trials. Local know-how, proper due diligence and AI are helpful in striking licensing deals in China, experts say. For t

Fierce Pharma ↗

Pharmacy

Inside agency view: Ogilvy Health on AI’s ‘light speed,’ nano influencers and the rise of Ria

• Healthcare agencies remain at the forefront of pharmaceutical marketing, but new technologies and shifting political dynamics are putting increasing pressure on the industry.

Fierce Pharma ↗

Pharmacy

Designing an agentic, future‑ready tech roadmap for emerging pharma

• JR Raelin of SynOx Therapeutics and Krishna GS of ZS discuss how emerging pharma teams can design scalable, compliant tech roadmaps as agentic AI expectations rise.

Fierce Pharma ↗